drugset / Trial / NCT06674577

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

NCT06674577

Phase 2 Enrolling by invitation 750 enrolled Vera Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.

Timeline

Start
2024-12-01
Primary completion
2031-05-21
Completion
2031-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Atacicept Protein / enzyme biologic 150 mg Subcutaneous